Catalyst
Slingshot members are tracking this event:
Merck And Pfizer Announce Two Pivotal Phase 3 Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sglt-2 Inhibitor, A1c Reductions, Type 2 Diabetes, Ertugliflozin, Vertis
